UCL Discovery
UCL home » Library Services » Electronic resources » UCL Discovery

Clinical outcomes and survival of patients with myeloma and lymphoma enrolled into phase I clinical trials

El-Sharkawi, D; Ng, C-H; Payne, EMC; Yong, KL; Ardeshna, KM; Khwaja, A; Townsend, W; (2019) Clinical outcomes and survival of patients with myeloma and lymphoma enrolled into phase I clinical trials. British Journal of Haematology , 185 (2) pp. 344-347. 10.1111/bjh.15457. Green open access

[img]
Preview
Text
Payne_post acceptance.pdf - Accepted version

Download (117kB) | Preview

Abstract

Phase I clinical trials are primarily designed to assess the safety and toxicity of a new agent and determine the recommended dose for further trials that assess efficacy. Patients entering these trials typically have multiply relapsed or refractory disease and would otherwise receive supportive treatment. The collective outcomes of patients enrolled onto phase I trials in solid tumors but not in hematological malignancies have previously been reported. We analyzed the overall outcomes and survival of 91 patients enrolled onto one of 14 Phase I and I/II trials for hematological malignancies at a dedicated early phase trials unit within a tertiary hematology unit. Median time on trial was 3.7 months (range 0-24), 32% experienced grade 3 or 4 adverse events. The overall response rate was 41%, overall survival 18 months (95% confidence intervals 5-30 months) and progression free survival 7 months (95% CI 1-13), although there was a significant difference according to underlying hematological cancer subtype. Response rate was strongly associated with survival time. On multivariate analysis, disease subtype and LDH at time of trial entry showed an association with survival rate. These results demonstrate that the outcomes of patients with hematiological malignancies entering phase I trials is better than expected.

Type: Article
Title: Clinical outcomes and survival of patients with myeloma and lymphoma enrolled into phase I clinical trials
Open access status: An open access version is available from UCL Discovery
DOI: 10.1111/bjh.15457
Publisher version: https://doi.org/10.1111/bjh.15457
Language: English
Additional information: This version is the author accepted manuscript. For information on re-use, please refer to the publisher’s terms and conditions.
Keywords: clinical trials, myeloma therapy, new drug development, new drugs for lymphoma
UCL classification: UCL > Provost and Vice Provost Offices
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Medical Sciences
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Medical Sciences > Cancer Institute
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Medical Sciences > Cancer Institute > Research Department of Haematology
URI: https://discovery.ucl.ac.uk/id/eprint/10050210
Downloads since deposit
21Downloads
Download activity - last month
Download activity - last 12 months
Downloads by country - last 12 months

Archive Staff Only

View Item View Item